Cellules souches
Les inhibiteurs de cellules souches sont des composés qui ciblent spécifiquement les cellules souches et leurs voies de signalisation, affectant leur capacité à s'auto-renouveler et à se différencier. Ces inhibiteurs sont essentiels dans la recherche axée sur le contrôle du comportement des cellules souches, la compréhension des processus de développement et le développement de thérapies pour des maladies comme le cancer, où les cellules souches sont censées jouer un rôle clé. Chez CymitQuimica, nous proposons une variété d'inhibiteurs de cellules souches pour soutenir vos recherches en médecine régénérative, biologie du développement et oncologie.
486 produits trouvés pour "Cellules souches"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
MYF-03-176
CAS :<p>MYF-03-176 is an orally active TEAD1/3/4 inhibitor with IC₅₀ values of 47/32/71 nM. inhibits TEAD transcriptional activity and cancer cell growth, antitumour.</p>Formule :C19H18F4N4O2Couleur et forme :SolidMasse moléculaire :410.37YAP/TAZ inhibitor-3
CAS :<p>YAP/TAZ inhibitor-3 (Compound 24) is a YAP/TAZ inhibitor applicable for relevant research within the life sciences field.</p>Formule :C21H18F3NO3Degré de pureté :99.63%Couleur et forme :SolidMasse moléculaire :389.37CP-352664
CAS :<p>CP-352664 is a JAK inhibitor with potency against JAK3, exhibiting an EC50 value of 210 nM. It holds potential for use in research related to organ transplant rejection and autoimmune diseases, such as rheumatoid arthritis.</p>Formule :C18H18N4Couleur et forme :SolidMasse moléculaire :290.36AJI-100
CAS :<p>AJI-100 serves as a dual-target inhibitor, effectively blocking Aurora kinase A and JAK2, with respective IC50 values of 12.7 nM and 18.5 nM. It inhibits T cell mitosis and cell polarity by directly targeting Aurora kinase A and reduces STAT3 phosphorylation by inhibiting JAK2 activation, consequently diminishing the differentiation of TH1 and TH17 cells. This compound is utilized in researching immune response regulation and the prevention of graft-versus-host disease (GVHD).</p>Formule :C17H14FN5OCouleur et forme :SolidMasse moléculaire :323.32JAK3 covalent inhibitor-1
CAS :<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Formule :C22H17FN6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.47STAT3-IN-8
CAS :<p>"STAT3-IN-8 (compound H172) is a potent inhibitor of STAT3 with potential applications in cancer research [1]."</p>Formule :C19H7F7N2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :444.26GDC-9918
CAS :<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Formule :C20H18F2N6O5SCouleur et forme :SolidMasse moléculaire :492.46(Rac)-SAG
CAS :<p>(Rac)-SAG, an isoform of SAG, is a potent Smoothened (Smo) receptor agonist (EC₅₀ = 3 nM; Kd = 59 nM) that activates the Hedgehog signaling pathway and counteracts Cyclopamine's inhibition of Smo [1] [2] [3].</p>Formule :C28H28ClN3OSCouleur et forme :SolidMasse moléculaire :490.06WZ-2-033
CAS :<p>WZ-2-033 is a potent STAT3 inhibitor. It inhibits proliferation, colony survival, migration, and invasion of MDA-MB-231, HCC70, and MDA-MB231-4175 cells, with IC50 values of 0.7, 1.3, and 1.3 μM respectively.</p>Formule :C25H18F3N3O4SCouleur et forme :SolidMasse moléculaire :513.49YAP/TAZ-TEAD-IN-2
<p>YAP/TAZ-TEAD-IN-2 (Compound 51) is a YAP/TAZ-TEAD inhibitor that disrupts the interaction between YAP/TAZ and TEAD. It inhibits the transcriptional activity of TEAD with an IC50 of 1.2 nM. Additionally, YAP/TAZ-TEAD-IN-2 suppresses the expression of target genes (Cyr61, CTGF, AXL, and Survivin) and the proliferation of breast cancer cells.</p>Formule :C19H20N2O3SCouleur et forme :SolidMasse moléculaire :356.44JAK1-IN-16
<p>JAK1-IN-16 (compound 4l) acts as an inhibitor of JAK1/STAT3 and effectively downregulates the expression of TLR4 protein.</p>Formule :C20H15ClF3N3OSCouleur et forme :SolidMasse moléculaire :437.87Casein kinase 1δ-IN-13
CAS :<p>Casein kinase1δ-IN-13 (compound 401) is an inhibitor of Casein kinase1δ. It is utilized in the research of neurodegenerative diseases.</p>Formule :C15H13N3O2SCouleur et forme :SolidMasse moléculaire :299.35STAT3-IN-35
CAS :<p>STAT3-IN-35 is a STAT3 inhibitor that binds to the SH2 domain. This compound inhibits the phosphorylation of STAT3 and exhibits antiproliferative activity in triple-negative breast cancer (TNBC) cell lines. Additionally, STAT3-IN-35 has demonstrated toxicity and potent antitumor activity in TNBC xenograft models.</p>Formule :C21H23NO4Couleur et forme :SolidMasse moléculaire :353.41ROCK/HDAC-IN-1
<p>ROCK/HDAC-IN-1 (Compound 10h) serves as an orally effective inhibitor of ROCK/HDAC. This compound suppresses ROCK1/2 (IC50: 254.9 nM, 58.18 nM) and HDAC1/2/3/6/8 (IC50: 9.09, 8.03, 6.26, 0.41, 7.69 nM). It stimulates the activation of DAMPs, notably calreticulin (CRT) exposure and HMGB1 release, suggesting its potential as an inducer of immunogenic cell death (ICD). ROCK/HDAC-IN-1 exhibits antiproliferative effects against breast cancer cells (IC50: 0.37 μM for MDA-MB-231 cells), inhibits tumor growth, activates T cells, and shows no significant toxicity.</p>Formule :C19H22N4O3SCouleur et forme :SolidMasse moléculaire :386.47GSK-3β inhibitor 20
CAS :<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Formule :C22H21N5O2SCouleur et forme :SolidMasse moléculaire :419.50MGD-28
CAS :<p>MGD-28 is a Cullin-CRBN-dependent IKZF family protein degrader for IKZF1 (Ikaros), IKZF2 (Helios), IKZF3 (Aiolos) ,and CK1α, antiproliferative.</p>Formule :C33H34FN7O3Degré de pureté :99.39%Couleur et forme :SolidMasse moléculaire :595.67(R)-9b
CAS :<p>(R)-9b is an effective inhibitor of the ACK1 tyrosine kinase (IC50=56 nM) and exhibits anticancer activity. It selectively targets ACK1 but also inhibits kinases in the JAK family, specifically JAK2 and Tyk2. (R)-9b is used in research related to hormone-regulated cancers, such as prostate cancer and breast cancer.</p>Formule :C20H27ClN6OCouleur et forme :SolidMasse moléculaire :402.92STAT3-IN-36
CAS :<p>STAT3-IN-36 (compound 11g) is a tritarget inhibitor that selectively targets LRPPRC, STAT3, and CDK1, exhibiting potent anticancer activity. This compound binds to LRPPRC, STAT3, and CDK1, demonstrating more effective anticancer effects than those of TMF or Capecitabine. Additionally, STAT3-IN-36 exhibits an IC50 value of 1.8 μM in HGC27 cells.</p>Formule :C30H24F2N2O9S2Couleur et forme :SolidMasse moléculaire :658.65JAK3-IN-7
CAS :<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Formule :C17H20N6ODegré de pureté :98.81%Couleur et forme :SolidMasse moléculaire :324.38PT109
CAS :<p>PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.</p>Formule :C23H31N3OS2Couleur et forme :SolidMasse moléculaire :429.64
